United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph).       if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitiv

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2) ]. tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (adcirca®* ). hypersensitivity reacti

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablets are con

United States - English - NLM (National Library of Medicine)

northstar rxllc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2) ]. tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (adcirca®* ). hypersensitivity reacti

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil tablets are contraindic

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil tablets are contraindic

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies (14.3)] . administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil tablets are contraindic

United States - English - NLM (National Library of Medicine)

vkt pharma private limited - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil tablets are used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see clinical studies ( 14.3)] . administration of tadalafil tablets to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology ( 12.2)] . tadalafil tablets are con

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of erectile dysfunction (ed). tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph). tadalafil tablets are indicated for the treatment of ed and the signs and symptoms of bph (ed/bph). if tadalafil is used with finasteride to initiate bph treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil beyond 26 weeks is unknown [see clinical studies (14.3)] .  administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. in clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [see clinical pharmacology (12.2)] . tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (tadalafil tablets or adcirca® ). hypersensitivity reactions